AN INTRODUCTION TO ALZHEIMER’S
DISEASE Watch the video here

TauRx exists to solve one of the world’s biggest challenges – beating Alzheimer’s and other degenerative brain diseases via a completely new approach Read more

We combine pioneering research and drug development Read more

Our protein aggregation inhibitors aim to halt disease progression by targeting the underlying pathology of dementia Read more

Protein aggregation inhibitor LMTX® is a patented novel chemical entity currently in development for the prevention of Alzheimer’s and bvFTD Read more

Phase 3 trials for LMTX® now completed - over 1,900 patients, across 20 countries Read more

Pioneering Science

The tau tangle pathway is a key driver of Alzheimer’s disease leading to loss of neuronal function, spread of pathology and clinical symptoms. View

Pioneering Science

Alzheimer's Innovations

TauRx’s tau aggregation inhibitors are the outcome of nearly 30 years of research, preclinical and clinical investigations. View

Alzheimer's Innovations

Clinical
Trials

An abstract from the second of TauRx's two Phase 3 trials in Alzheimer's disease was presented at CTAD 2016 on 8th December.
View

Clinical<br/>Trials

TauRx and LMTX

Claude Wischik, TauRx CEO, discusses the clinical development of LMTX, and what the recent Phase 3 results mean for TauRx’s on-going development programme.

TauRx’s Research

Claude Wischik explores TauRx’s broad-based research activities including its pioneering work on both the treatment and early diagnosis of AD.

Alzheimer’s Disease and Tau Pathology

Claude Wischik talks about how the Alzheimer’s research landscape has evolved over the past thirty years and the impact of the disease on patients and their families.